GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PetIQ Inc (NAS:PETQ) » Definitions » Debt-to-EBITDA

PetIQ (PETQ) Debt-to-EBITDA : 3.54 (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is PetIQ Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

PetIQ's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $15 Mil. PetIQ's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $450 Mil. PetIQ's annualized EBITDA for the quarter that ended in Mar. 2024 was $131 Mil. PetIQ's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was 3.54.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for PetIQ's Debt-to-EBITDA or its related term are showing as below:

PETQ' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.05   Med: 7.47   Max: 30.57
Current: 5.75

During the past 9 years, the highest Debt-to-EBITDA Ratio of PetIQ was 30.57. The lowest was 1.05. And the median was 7.47.

PETQ's Debt-to-EBITDA is ranked worse than
83.51% of 655 companies
in the Drug Manufacturers industry
Industry Median: 1.66 vs PETQ: 5.75

PetIQ Debt-to-EBITDA Historical Data

The historical data trend for PetIQ's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PetIQ Debt-to-EBITDA Chart

PetIQ Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only 20.89 17.43 9.34 30.57 5.75

PetIQ Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.27 3.90 4.57 -93.29 3.54

Competitive Comparison of PetIQ's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, PetIQ's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PetIQ's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PetIQ's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where PetIQ's Debt-to-EBITDA falls into.



PetIQ Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

PetIQ's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(16.203 + 452.099) / 81.411
=5.75

PetIQ's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(14.734 + 449.788) / 131.296
=3.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


PetIQ  (NAS:PETQ) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


PetIQ Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of PetIQ's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


PetIQ (PETQ) Business Description

Traded in Other Exchanges
Address
230 East Riverside Drive, Eagle, ID, USA, 83616
PetIQ Inc is a manufacturer and distributor of health and wellness products for dogs and cats. The company offers veterinarian-grade pet Rx medications, OTC flea and tick preventatives, vitamins treats, nutritional supplements, and hygiene products. The group operates in two segments namely the Products and Services segments. It also provides third-party products to retailers which for a long time were primarily available from veterinary clinics only. Its proprietary brands include PetIQ, PetArmor, VIP Petcare, VetIQ PetCare, VetIQ, Capstar, Advecta, SENTRY, Sergeants, TruProfen, Betsy Farms, PetAction, Minties, Vera and Delightibles. The company generates maximum revenue from Products segment.
Executives
William J. Carter officer: EVP, GENERAL COUNSEL C/O PETIQ, INC., 230 E. RIVERSIDE DR., EAGLE ID 83616
John Paul Pearson officer: EVP, Services & Manufactured C/O PETIQ, INC., 230 E. RIVERSIDE DR., EAGLE ID 83616
Robert Michael Herrman officer: General Counsel and Secretary 923 SOUTH BRIDGEWAY PLACE, EAGLE ID 83616
Michael A Smith officer: EVP - Products 923 S. BRIDGEWAY PLACE, C/O PETIQ, INC., EAGLE ID 83616
Kimberly Lefko director 923 S. BRIDGEWAY PLACE, EAGLE ID 83616
Sheryl Oloughlin director 923 S. BRIDGEWAY PLACE, EAGLE ID 83616
Scott Huff director 923. S. BRIDGEWAY PLACE, EAGLE ID 83616
Allan Hall director C/O PETIQ, INC., 230 E. RIVERSIDE DR., EAGLE ID 83616
Zvi Glasman officer: Chief Financial Officer C/O FOX FACTORY HOLDING CORP., 915 DISC DRIVE, SCOTTS VALLEY CA 95066
Kenneth C. Walker director C/O PETIQ, INC., 230 E. RIVERSIDE DR., EAGLE ID 83616
Susan Sholtis director C/O PETIQ, INC., 500 E. SHORE DRIVE, SUITE 120, EAGLE ID 83616
Mccord Christensen director, officer: Chief Executive Officer 500 EAST SHORE DRIVE, SUITE 120, EAGLE ID 83616
John Newland officer: Chief Financial Officer C/O TRUE SCIENCE LLC, 500 E. SHORE DRIVE SUITE 120, EAGLE ID 83616
Ronald Kennedy director, 10 percent owner 500 EAST SHORE DR, SUITE 120, EAGLE ID 83616
Ecp Helios Partners Iv, L.p. 10 percent owner 437 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10022